Sanofi News - SAN

Sanofi: Information concerning the total number of voting rights and shares – June 2024

Sanofi: Information concerning the total number of voting rights and shares – June 2024 Information concerning the total number of voting rights...

Sanofi: Informations relatives au nombre de droits de vote et d'actions – Juin 2024

Sanofi: Informations relatives au nombre de droits de vote et d'actions – Juin 2024 Informations relatives au nombre total de droits de vote...

Press Release: NEJM publishes ALTUVIIIO XTEND-Kids phase 3 data supporting its potential to transform the treatment landscape for children with severe hemophilia A

NEJM publishes ALTUVIIIO XTEND-Kids phase 3 data supporting its potential to transform the treatment...

Press Release: NEJM publishes ALTUVIIIO XTEND-Kids phase 3 data supporting its potential to transform the treatment landscape for children with severe hemophilia A

Press Release: NEJM publishes ALTUVIIIO XTEND-Kids phase 3 data supporting its potential to transform the treatment landscape for children with...

Communiqué de presse : Le NEJM publie les données de phase III de l’étude XTEND-Kids montrant qu’ALTUVIIIO a le potentiel de transformer la prise en charge thérapeutique des enfants atteints d’hémophilie A sévère

Communiqué de presse : Le NEJM publie les données de phase III de l’étude XTEND-Kids montrant qu’ALTUVIIIO a le potentiel de transformer la prise...

Communiqué de presse : Dupixent devient le tout premier médicament ciblé pour le traitement de la BPCO approuvé dans l’Union européenne

Communiqué de presse : Dupixent devient le tout premier médicament ciblé pour le traitement de la BPCO approuvé dans l’Union européenne...

Press Release: Dupixent positive phase 3 data in children one to 11 years of age with eosinophilic esophagitis published in NEJM

Dupixent positive phase 3 data in children one to 11 years of age with eosinophilic esophagitis published in...

Press Release: Availability of the Q2 2024 Aide-mémoire

Press Release: Availability of the Q2 2024 Aide-mémoire Availability of the Q2 2024 Aide-mémoire Paris, France – June 25, 2024. Sanofi...

Press Release: Audrey Duval Derveloy appointed Global Head of Corporate Affairs, member of Sanofi’s Executive Committee

Press Release: Audrey Duval Derveloy appointed Global Head of Corporate Affairs, member of Sanofi’s Executive Committee Audrey Duval Derveloy...

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Sanofi (SAN)

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

SAN News

Sanofi: Information concerning the total number of voting rights and shares – June 2024

Sanofi: Informations relatives au nombre de droits de vote et d'actions – Juin 2024

Press Release: NEJM publishes ALTUVIIIO XTEND-Kids phase 3 data supporting its potential to transform the treatment landscape for children with severe hemophilia A

Press Release: NEJM publishes ALTUVIIIO XTEND-Kids phase 3 data supporting its potential to transform the treatment landscape for children with severe hemophilia A

Communiqué de presse : Le NEJM publie les données de phase III de l’étude XTEND-Kids montrant qu’ALTUVIIIO a le potentiel de transformer la prise en charge thérapeutique des enfants atteints d’hémophilie A sévère

Communiqué de presse : Dupixent devient le tout premier médicament ciblé pour le traitement de la BPCO approuvé dans l’Union européenne

Press Release: Dupixent positive phase 3 data in children one to 11 years of age with eosinophilic esophagitis published in NEJM

Press Release: Availability of the Q2 2024 Aide-mémoire

Press Release: Audrey Duval Derveloy appointed Global Head of Corporate Affairs, member of Sanofi’s Executive Committee

SAN Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Sanofi (SAN) News

Sanofi (SAN)

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

SAN News

Sanofi: Information concerning the total number of voting rights and shares – June 2024

Sanofi: Informations relatives au nombre de droits de vote et d'actions – Juin 2024

Press Release: NEJM publishes ALTUVIIIO XTEND-Kids phase 3 data supporting its potential to transform the treatment landscape for children with severe hemophilia A

Press Release: NEJM publishes ALTUVIIIO XTEND-Kids phase 3 data supporting its potential to transform the treatment landscape for children with severe hemophilia A

Communiqué de presse : Le NEJM publie les données de phase III de l’étude XTEND-Kids montrant qu’ALTUVIIIO a le potentiel de transformer la prise en charge thérapeutique des enfants atteints d’hémophilie A sévère

Communiqué de presse : Dupixent devient le tout premier médicament ciblé pour le traitement de la BPCO approuvé dans l’Union européenne

Press Release: Dupixent positive phase 3 data in children one to 11 years of age with eosinophilic esophagitis published in NEJM

Press Release: Availability of the Q2 2024 Aide-mémoire

Press Release: Audrey Duval Derveloy appointed Global Head of Corporate Affairs, member of Sanofi’s Executive Committee

SAN Discussion

Your Recent History